By meeting challenges in caring for patients with chronic obstructive pulmonary dieases head-on, primary care doctors have an opportunity to reduce the potential for unnecessary or sub-optimal care while improving patient outcomes.
Nearly 28.5 million Americans are uninsured or underinsured, leaving them at risk for medical costs they may not be able to afford. Surprise billing is particularly problematic for acute, or emergency cases.
Federal and state officials have implemented policies and safeguards to slow transmission of the virus. Most troubling were state moratoriums on “elective” surgical procedures.
The cost and care implications of osteoporosis are expected to grow substantially as the baby boomers age. A study published this year found the total annual cost of providing care for osteoporotic fractures among Medicare beneficiaries, including direct medical costs as well as indirect societal costs related to productivity losses and informal caregiving, would rise from $57 billion in 2018 to $95 billion in 2040 unless strategies are implemented to prevent fractures.
Better outpatient medication adherence reduces the likelihood of readmission after a recent myocardial infarction.
A poll conducted by PatientsLikeMe shows that cancer patients have the same concerns as the general population about healthcare costs, but see benefits in the law that the healthy may have overlooked.
A critical obstacle to chronic disease management is that the patients most likely to benefit from primary care aren’t necessarily the patients who see their providers. Digital health helps providers support patients outside the traditional 4 walls of the doctor’s office.
CDC has created Prevent2 to help employers find those employees most at risk of diabetes.
In an era when healthcare is extremely expensive, there are many opinions on how involved our federal government should be in bringing drug prices down. However, there is one particular drug-pricing crisis that many can agree needs to be addressed sooner rather than later: the insulin crisis.
It's time to finally put an end to “what the market will bear” as a method of pricing prescription drugs.
Changes to Medigap as part of the Medicare Access and CHIP Reauthorization Act go into action beginning next year.
To have true utility, value models to assess the worthiness of treatments must have robust processes in place to incorporate the patient voice.
With the dramatic shift toward precision medicine in cancer care, health systems, pharmaceutical companies and technology companies should ensure that the oncologist is at the center of their strategy.
Only 20% of a person’s health can be attributed to healthcare. What happens outside the hospital and clinic doors is far more important in determining how healthy a person or population will be.
Taking a bold step into the world of bundled payment models can help an organization transform itself, but it could fail.
It's time for curated, customer-centric thinking to come to healthcare, writes healthcare industry executives.
Just as physical therapists (PT) or occupational therapists (OT) help patients overcome barriers to increased mobility, referral challenges can be overcome with the right people, processes, and technology.
Patient behavior is perhaps the final frontier to concur in our quest of making our population healthier. But, how can we change the health behavior of nearly 200,000,000 Americans? A SXSW panel discussed some individual approaches using innovative technology.
In recent years, fatal overdoses from fentanyl have drastically increased across the nation, with the number of deaths nearly doubling each year from 2013 through 2016.
When people seek price information before getting care, they are not just looking for data online-they are turning to providers and staff for face-to-face help.
The future is bright with technological innovation intended to improve every corner of our lives and, accordingly, there has been a virtual explosion in advancements designed to address the many challenges faced by patients, hospitals, and healthcare professionals.
In this article, we'll explain how healthcare organizations can drive patient engagement and satisfaction while improving outcomes by supporting the whole person in one comprehensive digital solution.
As Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) get closer to market, the safety question is one of the remaining pieces of the puzzle that unfortunately can't be solved immediately until real-world data starts to become available. However, as payers assess the risk-benefit of Repatha and Praluent vs the gold standard statins, there are questions that CAN be answered immediately.
Organizations should step up and improve rural health by offering new, innovative ways to improve access to the care that rural residents so desperately need.